Aurora Kinase Inhibition: A New Light in the Sky?

Journal of Medicinal Chemistry

Volumn 58, Issue 13, 2015, Pages 5186-5188

  Linardopoulos, Spiros ^a   Blagg, Julian ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 900; AURORA A KINASE; AURORA B KINASE; AURORA KINASE INHIBITOR; UNCLASSIFIED DRUG; AURORA KINASE; N-(4-((3-(2-AMINO-4-PYRIMIDINYL)-2-PYRIDINYL)OXY)PHENYL)-4-(4-METHYL-2-THIENYL)-1-PHTHALAZINAMINE; PHTHALAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANTIPROLIFERATIVE ACTIVITY; BINDING KINETICS; COLORECTAL CANCER CELL LINE; DRUG CLEARANCE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IC50; IN VITRO STUDY; NONHUMAN; REVIEW; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; NEOPLASMS;

AURORA KINASES; HUMANS; NEOPLASMS; PHTHALAZINES; PROTEIN KINASE INHIBITORS;

EID: 84937468263     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00918     Document Type: Review

References (12)

1. Carmena, M.; Ruchaud, S.; Earnshaw, W. C. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins Curr. Opin. Cell. Biol. 2009, 21, 796-805
2. Malumbres, M.; Barbacid, M. Cell cycle kinases in cancer Curr. Opin. Genet. Dev. 2007, 17, 60-5
3. Brockmann, M.; Poon, E.; Berry, T.; Carstensen, A.; Deubzer, H. E.; Rycak, L.; Jamin, Y.; Thway, K.; Robinson, S. P.; Roels, F.; Witt, O.; Fischer, M.; Chesler, L.; Eilers, M. Small molecule inhibitors of Aurora-A induce proteasomal degradation of N-Myc in childhood neuroblastoma Cancer Cell 2013, 24, 75-89
4. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools Chem. Biol. 2010, 17, 561-577
5. Bunnage, M. E.; Chekler, E. L.; Jones, L. H. Target validation using chemical probes Nat. Chem. Biol. 2013, 9, 195-199
6. Gustafson, W. C.; Meyerowitz, J. G.; Nekritz, E. A.; Chen, J.; Benes, C.; Charron, E.; Simonds, E. F.; Seeger, R.; Matthay, K. K.; Hertz, N. T.; Eilers, M.; Shokat, K. M.; Weiss, W. A. Drugging MYCN through an allosteric transition in Aurora kinase A Cancer Cell 2014, 26, 414-427
7. Geuns-Meyer, S.; Cee, V. J.; Deak, H. L.; Du, B.; Hodous, B. L.; Nguyen, H. N.; Olivieri, P. R.; Schenkel, L. B.; Vaida, K. R.; Andrews, P.; Bak, A.; Be, X.; Beltran, P. J.; Bush, T. L.; Chaves, M. K.; Chung, G.; Dai, Y.; Eden, P.; Hanestad, K.; Huang, L.; Lin, M.-H. J.; Tang, J.; Ziegler, B.; Radinsky, R.; Kendall, R.; Patel, V. F.; Payton, M. Discovery of N -(4-(3-(2-aminopyrimidin-4-yl)pyridin-2-yloxy)phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine (AMG 900), a highly selective, orally bioavailable inhibitor of Aurora kinases with activity against multidrug-resistant cancer cell lines. J. Med. Chem. 2015, DOI: 10.1021/acs.jmedchem.5b00183.
8. Cee, V. J.; Schenkel, L. B.; Hodous, B. L.; Deak, H. L.; Nguyen, H. N.; Olivieri, P. R.; Romero, K.; Bak, A.; Be, X.; Bellon, S.; Bush, T. L.; Cheng, A. C.; Chung, G.; Coats, S.; Eden, P. M.; Hanestad, K.; Gallant, P. L.; Gu, Y.; Huang, X.; Kendall, R. L.; Lin, M. H.; Morrison, M. J.; Patel, V. F.; Radinsky, R.; Rose, P. E.; Ross, S.; Sun, J. R.; Tang, J.; Zhao, H.; Payton, M.; Geuns-Meyer, S. D. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine Aurora kinase inhibitor J. Med. Chem. 2010, 53, 6368-6377
9. Payton, M.; Bush, T. L.; Chung, G.; Ziegler, B.; Eden, P.; McElroy, P.; Ross, S.; Cee, V. J.; Deak, H. L.; Hodous, B. L.; Nguyen, H. N.; Olivieri, P. R.; Romero, K.; Schenkel, L. B.; Bak, A.; Stanton, M.; Dussault, I.; Patel, V. F.; Geuns-Meyer, S.; Radinsky, R.; Kendall, R. L. Preclinical evaluation of AMG 900, a novel potent and highly selective pan-Aurora kinase inhibitor with activity in taxane-resistant tumor cell lines Cancer Res. 2010, 70, 9846-9854
10. Bush, T. L.; Payton, M.; Heller, S.; Chung, G.; Hanestad, K.; Rottman, J. B.; Loberg, R.; Friberg, G.; Kendall, R. L.; Saffran, D.; Radinsky, R. AMG 900, a small-molecule inhibitor of Aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models Mol. Cancer Ther. 2013, 12, 2356-2366
11. Workman, P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics Mol. Cancer Ther. 2003, 2, 131-138
12. Smith, D. A.; Di, L.; Kerns, E. H. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery Nat. Rev. Drug Discovery 2010, 9, 929-939